Does the media prefer KRYS or TARS?

In the previous week, Krystal Biotech and Krystal Biotech both had 7 articles in the media. Tarsus Pharmaceuticals' average media sentiment score of 0.43 beat Krystal Biotech's score of 0.06 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tarsus Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CYTK or TARS?

In the previous week, Cytokinetics had 1 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 8 mentions for Cytokinetics and 7 mentions for Tarsus Pharmaceuticals. Cytokinetics' average media sentiment score of 0.85 beat Tarsus Pharmaceuticals' score of 0.43 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NUVL or TARS?

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Nuvalent. MarketBeat recorded 7 mentions for Tarsus Pharmaceuticals and 4 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.80 beat Tarsus Pharmaceuticals' score of 0.43 indicating that Nuvalent is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SYRE or TARS?

In the previous week, Spyre Therapeutics had 2 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 9 mentions for Spyre Therapeutics and 7 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.43 beat Spyre Therapeutics' score of 0.26 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tarsus Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Tarsus Pharmaceuticals (TARS) Competitors

$62.92 -1.42 (-2.21%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$62.85 -0.07 (-0.11%)

As of 06/26/2026 07:10 PM Eastern

Compare

TARS vs. KRYS, CYTK, NUVL, SYRE, and PRAX

Should you buy Tarsus Pharmaceuticals stock or one of its competitors? MarketBeat compares Tarsus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tarsus Pharmaceuticals include Krystal Biotech (KRYS), Cytokinetics (CYTK), Nuvalent (NUVL), Spyre Therapeutics (SYRE), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.

How does Tarsus Pharmaceuticals compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Krystal Biotech has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

Krystal Biotech currently has a consensus price target of $340.56, indicating a potential downside of 8.51%. Tarsus Pharmaceuticals has a consensus price target of $90.67, indicating a potential upside of 44.10%. Given Tarsus Pharmaceuticals' higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Krystal Biotech and Krystal Biotech both had 7 articles in the media. Tarsus Pharmaceuticals' average media sentiment score of 0.43 beat Krystal Biotech's score of 0.06 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tarsus Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Krystal Biotech has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	28.20	$204.83M	$7.48	49.77
Tarsus Pharmaceuticals	$535.08M	5.06	-$66.42M	-$1.14	N/A

Krystal Biotech has a net margin of 53.92% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Krystal Biotech's return on equity of 19.25% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

Summary

Krystal Biotech beats Tarsus Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Cytokinetics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

In the previous week, Cytokinetics had 1 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 8 mentions for Cytokinetics and 7 mentions for Tarsus Pharmaceuticals. Cytokinetics' average media sentiment score of 0.85 beat Tarsus Pharmaceuticals' score of 0.43 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cytokinetics currently has a consensus price target of $100.20, indicating a potential upside of 21.95%. Tarsus Pharmaceuticals has a consensus price target of $90.67, indicating a potential upside of 44.10%. Given Tarsus Pharmaceuticals' higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Tarsus Pharmaceuticals has higher revenue and earnings than Cytokinetics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$105.82M	96.62	-$784.96M	-$6.84	N/A
Tarsus Pharmaceuticals	$535.08M	5.06	-$66.42M	-$1.14	N/A

Tarsus Pharmaceuticals has a net margin of -9.02% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 2.6% of Cytokinetics shares are held by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Tarsus Pharmaceuticals beats Cytokinetics on 9 of the 16 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Nuvalent. MarketBeat recorded 7 mentions for Tarsus Pharmaceuticals and 4 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.80 beat Tarsus Pharmaceuticals' score of 0.43 indicating that Nuvalent is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvalent has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

Tarsus Pharmaceuticals has higher revenue and earnings than Nuvalent. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Tarsus Pharmaceuticals	$535.08M	5.06	-$66.42M	-$1.14	N/A

Nuvalent has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Nuvalent presently has a consensus target price of $127.73, indicating a potential upside of 3.41%. Tarsus Pharmaceuticals has a consensus target price of $90.67, indicating a potential upside of 44.10%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Summary

Tarsus Pharmaceuticals beats Nuvalent on 10 of the 15 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Spyre Therapeutics has a beta of 3.05, suggesting that its stock price is 205% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

In the previous week, Spyre Therapeutics had 2 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 9 mentions for Spyre Therapeutics and 7 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.43 beat Spyre Therapeutics' score of 0.26 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tarsus Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Spyre Therapeutics has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

Spyre Therapeutics presently has a consensus price target of $95.83, indicating a potential upside of 9.04%. Tarsus Pharmaceuticals has a consensus price target of $90.67, indicating a potential upside of 44.10%. Given Tarsus Pharmaceuticals' higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Tarsus Pharmaceuticals has higher revenue and earnings than Spyre Therapeutics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,575.69	-$155.20M	-$2.08	N/A
Tarsus Pharmaceuticals	$535.08M	5.06	-$66.42M	-$1.14	N/A

Summary

Spyre Therapeutics and Tarsus Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Praxis Precision Medicines?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Tarsus Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$535.08M	5.06	-$66.42M	-$1.14	N/A
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$13.37	N/A

Tarsus Pharmaceuticals has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, meaning that its share price is 171% more volatile than the broader market.

Tarsus Pharmaceuticals currently has a consensus target price of $90.67, suggesting a potential upside of 44.10%. Praxis Precision Medicines has a consensus target price of $566.21, suggesting a potential upside of 72.74%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95

In the previous week, Praxis Precision Medicines had 3 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 10 mentions for Praxis Precision Medicines and 7 mentions for Tarsus Pharmaceuticals. Praxis Precision Medicines' average media sentiment score of 0.50 beat Tarsus Pharmaceuticals' score of 0.43 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Praxis Precision Medicines has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Summary

Praxis Precision Medicines beats Tarsus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Tarsus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TARS vs. The Competition

Export

Metric	Tarsus Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.77B	$3.55B	$6.70B	$12.22B
Dividend Yield	N/A	2.25%	2.67%	6.13%
P/E Ratio	-55.19	21.56	25.76	24.17
Price / Sales	5.06	334.67	559.68	101.60
Price / Cash	N/A	137.38	46.99	54.37
Price / Book	7.78	8.34	10.77	6.35
Net Income	-$66.42M	$23.91M	$3.57B	$337.63M
7 Day Performance	-0.38%	3.38%	2.15%	0.06%
1 Month Performance	4.76%	1.51%	1.06%	-0.15%
1 Year Performance	55.94%	65.14%	34.16%	27.55%

Tarsus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TARS Tarsus Pharmaceuticals	3.2939 of 5 stars	$62.92 -2.2%	$90.67 +44.1%	+56.0%	$2.77B	$535.08M	N/A	50	News Coverage High Trading Volume
KRYS Krystal Biotech	2.2227 of 5 stars	$345.02 +0.5%	$340.56 -1.3%	+161.1%	$10.15B	$417.30M	46.01	210	Insider Trade
CYTK Cytokinetics	2.8416 of 5 stars	$79.69 +0.7%	$99.30 +24.6%	+142.3%	$9.88B	$88.04M	N/A	250	Analyst Forecast Insider Trade
NUVL Nuvalent	2.467 of 5 stars	$123.44 +0.0%	$131.15 +6.2%	+56.1%	$9.75B	N/A	N/A	40	Analyst Downgrade Short Interest Decrease
SYRE Spyre Therapeutics	1.7805 of 5 stars	$98.23 -2.1%	$95.83 -2.4%	+448.6%	$8.50B	$890K	N/A	73	Analyst Forecast Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TARS) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tarsus Pharmaceuticals (TARS) Competitors

TARS vs. KRYS, CYTK, NUVL, SYRE, and PRAX

How does Tarsus Pharmaceuticals compare to Krystal Biotech?

Summary

How does Tarsus Pharmaceuticals compare to Cytokinetics?

Summary

How does Tarsus Pharmaceuticals compare to Nuvalent?

Summary

How does Tarsus Pharmaceuticals compare to Spyre Therapeutics?

Summary

How does Tarsus Pharmaceuticals compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS vs. The Competition

Tarsus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tarsus Pharmaceuticals (TARS) Competitors

TARS vs. KRYS, CYTK, NUVL, SYRE, and PRAX

How does Tarsus Pharmaceuticals compare to Krystal Biotech?

Which has more risk & volatility, KRYS or TARS?

Do analysts prefer KRYS or TARS?

Do institutionals and insiders believe in KRYS or TARS?

Does the media prefer KRYS or TARS?

Which has stronger earnings & valuation, KRYS or TARS?

Is KRYS or TARS more profitable?

Summary

How does Tarsus Pharmaceuticals compare to Cytokinetics?

Which has more volatility and risk, CYTK or TARS?

Does the media prefer CYTK or TARS?

Do analysts prefer CYTK or TARS?

Which has higher earnings and valuation, CYTK or TARS?

Is CYTK or TARS more profitable?

Do insiders & institutionals believe in CYTK or TARS?

Summary

How does Tarsus Pharmaceuticals compare to Nuvalent?

Does the media prefer NUVL or TARS?

Which has more risk and volatility, NUVL or TARS?

Which has higher valuation & earnings, NUVL or TARS?

Is NUVL or TARS more profitable?

Do insiders and institutionals believe in NUVL or TARS?

Do analysts recommend NUVL or TARS?

Summary

How does Tarsus Pharmaceuticals compare to Spyre Therapeutics?

Which has more risk and volatility, SYRE or TARS?

Does the media refer more to SYRE or TARS?

Do insiders & institutionals hold more shares of SYRE or TARS?

Is SYRE or TARS more profitable?

Do analysts prefer SYRE or TARS?

Which has preferable earnings & valuation, SYRE or TARS?

Summary

How does Tarsus Pharmaceuticals compare to Praxis Precision Medicines?

Which has preferable valuation and earnings, TARS or PRAX?

Which has more volatility & risk, TARS or PRAX?

Do analysts recommend TARS or PRAX?

Does the media refer more to TARS or PRAX?

Do institutionals and insiders hold more shares of TARS or PRAX?

Is TARS or PRAX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS vs. The Competition

Tarsus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools